2-硝基-3-氯苯甲酸甲酯 | 42087-81-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-硝基-3-氯苯甲酸甲酯
• 中文别名: 3-氯-2-硝基苯甲酸甲酯
• 英文名称: methyl 3-chloro-2-nitrobenzoate
• 英文别名: 3-chloro-2-nitrobenzoic acid methyl ester
• CAS: 42087-81-0
• 化学式: C₈H₆ClNO₄
• mdl: MFCD04038813
• 分子量: 215.593
• InChiKey: VTWUVGLVDQXCJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-chloro-2-nitrobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-chloro-2-nitrobenzoate
CAS number: 42087-81-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6ClNO4
Molecular weight: 215.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-硝基-3-氯苯甲酸甲酯 在 platinum(IV) oxide 吡啶 、 盐酸 、 sodium tetrahydroborate 、 PPA 、 4 A molecular sieve 、 potassium tert-butylate 、 氢气 、 potassium carbonate 、 三乙胺 、 tin(ll) chloride 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 20.0~120.0 ℃ 、101.33 kPa 条件下， 反应 21.5h， 生成 9-chloro-5-(N-methylamino)-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine
  参考文献：
  名称：

  7-氯-5-羟基-1- [2-甲基-4-（2-甲基苯甲酰基-氨基）苯甲酰基] -2,3,4,5-四氢-1H-1-苯并ze庚因（OPC-41061）：有力口服活性非肽精氨酸加压素V2受体拮抗剂。

  摘要：

  我们先前报道了一系列苯并ze庚因衍生物作为口服活性非肽精氨酸加压素（AVP）V2受体拮抗剂。在对铅结构OPC-31260进行结构评估和优化后，苯并ze庚因上的7-Cl部分和氨基苯甲酰基部分上的2-CH3引入增强了其口服活性。新的AVP-V2选择性拮抗剂OPC-41061被确定为有效的口服活性剂。

  DOI：

  10.1016/s0968-0896(99)00101-7
• 作为产物：
  描述：

  2,3-二氯苯甲酸 在 sodium tungstate (VI) dihydrate 、 硫酸 、 四丁基溴化铵 、 氨 、 双氧水 、 potassium carbonate 、 copper(l) chloride 作用下， 以 甲醇 、 水 、 甲苯 为溶剂， 20.0~130.0 ℃ 、3.04 MPa 条件下， 反应 35.0h， 生成 2-硝基-3-氯苯甲酸甲酯
  参考文献：
  名称：

  METHOD FOR PRODUCING NITROBENZENE COMPOUND

  摘要：

  一种用于制备由通式（2）表示的硝基苯化合物的方法，其中R1和R5相同或不同，每个是卤素原子或另一个官能团，而R2、R3和R4相同或不同，每个是氢原子或另一个官能团，包括在酸性条件下在钨化合物存在下用过氧化氢氧化由通式（1）表示的苯胺化合物，其中R1、R2、R3、R4和R5与上述相同，随后在中性至碱性条件下用过氧化氢氧化。

  公开号：

  US20140163256A1

文献信息

• Constrained compounds as CGRP-receptor antagonists
  申请人：Chaturvedula V. Prasad

  公开号：US20060094707A1

  公开（公告）日：2006-05-04

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  这项发明涵盖了受限的双环和三环CGRP受体拮抗剂，用于识别它们的方法，包含它们的药物组合物，以及它们在治疗偏头痛和其他头痛、神经源性血管舒张、神经源性炎症、热损伤、循环性休克、与绝经期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））以及其他可以通过CGRP受体拮抗来治疗的疾病的治疗方法。
• CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS
  申请人：Mercer Stephen E.

  公开号：US20070259850A1

  公开（公告）日：2007-11-08

  The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

  这项发明涵盖了受限的双环和三环CGRP受体拮抗剂，用于识别它们的方法，包括它们的药物组合物，以及在治疗偏头痛和其他头痛、神经源性血管舒张、神经源性炎症、热损伤、循环性休克、与绝经期相关的潮红、气道炎症性疾病（如哮喘和慢性阻塞性肺病（COPD））以及其他可以通过CGRP受体拮抗来治疗的疾病的治疗方法。
• Inhibitors of protein tyrosine phosphatase 1B
  申请人：Lee Jinbo

  公开号：US20050203081A1

  公开（公告）日：2005-09-15

  Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.

  蛋白质酪氨酸磷酸酶（PTPases），如PTP1B，在调节广泛的细胞反应，如胰岛素信号传导中发挥作用。取代的并环融合噻吩化合物可以抑制PTP1B，从而增加胰岛素敏感性。因此，PTP1B的抑制可以提供一种治疗PTPase介导的疾病，如糖尿病的替代方法。
• Pd-Catalyzed Denitrative Intramolecular C–H Arylation
  作者：Kitty K. Asahara、Toshimasa Okita、Ami N. Saito、Kei Muto、Yoshiaki Nakao、Junichiro Yamaguchi

  DOI：10.1021/acs.orglett.9b01593

  日期：2019.6.21

  A Pd-catalyzed intramolecular C–H arylation of nitroarenes has been developed. Nitroarenes bearing tethered aryl groups at the ortho-position can be readily prepared in one step from 2-halonitroarenes by a nucleophilic aromatic substitution (SNAr). Under Pd/BrettPhos catalysis, activations of the C–NO2 bond as well as the C–H bond on arenes generated the corresponding biaryl linkage in moderate to

  已经开发了钯催化的硝基芳烃的分子内C–H芳基化反应。硝基芳烃轴承拴系的芳基在邻位-位可以在从2-halonitroarenes一个步骤通过亲核芳族取代（S容易地制备Ñ AR）。在Pd / BrettPhos催化下，芳烃上C–NO 2键以及C–H键的活化产生了相应的联芳基键合，产率中等至极佳。
• Triptycene‐Based, Carboxylate‐Bridged Biomimetic Diiron(II) Complexes
  作者：Yang Li、Chan Myae Myae Soe、Justin J. Wilson、Suan Lian Tuang、Ulf‐Peter Apfel、Stephen J. Lippard

  DOI：10.1002/ejic.201201387

  日期：2013.4.12

  that the desired diiron(II) complex could be obtained with a 1:2:1 ratio of L3:Fe(OTf)2(MeCN)2:external carboxylate reactants. X-ray crystallographic studies of two diiron complexes derived in this manner from L3 revealed their formulas to be [Fe2L3(μ-OH)(μ-O2CR)(OTf)2], where R = 2,6-bis(p-tolyl)benzoate (7) or triphenylacetate (8). The structures are similar to that of a diiron complex derived from L1

  基于三苯乙烯的双（苯并咪唑）酯配体 L3 旨在增强杂环氮原子相对于第一代双（苯并恶唑）类似物 L1 和 L2 的给电子能力。设计并执行了 L3 的收敛合成。使用紫外-可见光谱的三组分滴定实验表明，当 L3:Fe(OTf)2(MeCN)2:外部羧酸盐反应物的比例为 1:2:1 时，可以获得所需的二铁 (II) 配合物。以这种方式从 L3 衍生的两种二铁配合物的 X 射线晶体学研究表明它们的分子式为 [Fe2L3(μ-OH)(μ-O2CR)(OTf)2]，其中 R = 2,6-bis(p-tolyl )苯甲酸酯 (7) 或三苯乙酸酯 (8)。这些结构类似于衍生自 L1 的二铁络合物的结构，[Fe2L1(μ-OH)(μ-O2CArTol)(OTf)2] (9) 显着的区别在于，在 7 和 8 中，铁的几何形状更类似于方形锥体而不是三角双锥体。7 和 8 的穆斯堡尔光谱分析表明存在高自旋二铁 (II)